Novartis AG (SWX:NOVN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 200.67B |
| Revenue (ttm) | 44.95B |
| Net Income (ttm) | 11.48B |
| Shares Out | 1.92B |
| EPS (ttm) | 5.82 |
| PE Ratio | 17.97 |
| Forward PE | 14.83 |
| Dividend | 3.50 (3.40%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 3,545,611 |
| Average Volume | 2,874,744 |
| Open | 103.76 |
| Previous Close | 103.00 |
| Day's Range | 103.26 - 105.12 |
| 52-Week Range | 81.10 - 106.88 |
| Beta | 0.44 |
| RSI | 56.27 |
| Earnings Date | Oct 28, 2025 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in USD Financial StatementsNews
FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults
On Monday, the U.S. Food and Drug Administration (FDA) approved Novartis AG's (NYSE: NVS) Itvisma (onasemnogene abeparvovec-brve) for children two years and older, teens, and adults with spinal muscul...
Novartis plans to cut up to 550 jobs at Swiss facility
Novartis said on Tuesday up to 550 full-time jobs could be cut by the end of 2027 at the Swiss pharmaceutical company's Stein facility near Basel in northern Switzerland.
Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS
Basel, November 25, 2025 – Novartis will present data from over 70 abstracts, including investigator-initiated trials at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition and 2...
Muscular Dystrophy Association Calls FDA Approval of Novartis' Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community
The only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA). The only gene replacement therapy for children two years and older, teens, and...
FDA approves Novartis' gene therapy for rare muscle disorder
U.S. Food and Drug Administration has approved Novartis' gene therapy for a type of rare muscle disorder, the drugmaker said on Monday.
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III s...
Novartis AG (NVS) Shareholder/Analyst Call Transcript
Novartis AG ( NVS) Shareholder/Analyst Call November 20, 2025 4:15 AM EST Company Participants Victor Bulto - President of US Angelika Jahreis - Global Head of Development Unit Immunology, Hepatology...
Novartis AG (NVS) Shareholder/Analyst Call Transcript
Novartis AG (NVS) Shareholder/Analyst Call November 20, 2025 3:00 AM ESTCompany ParticipantsSloan Simpson - Global Head of Investor RelationsVasant...
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts
Novartis AG (NYSE: NVS) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well int...
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts
Novartis AG (NYSE: NVS) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into...
Novartis Issues Updated Mid-term Sales Guidance; Upgrades Peak Sales Guidance For Kisqali, Scemblix
(RTTNews) - Novartis (NVS) announced its mid-term guidance to 2025-2030 of a sales CAGR of 5-6% cc. The company noted that the updated outlook follows upgrade of 2024-2029 guidance to 6% cc. Also, the...
Novartis (NVS) Projects Robust Growth with Updated Sales Guidance
Novartis (NVS) Projects Robust Growth with Updated Sales Guidance
Novartis Lifts Outlook With Stronger Peak Sales Forecasts
Novartis Lifts Outlook With Stronger Peak Sales Forecasts
Novartis Lifts Outlook With Stronger Peak Sales Forecasts(edit)
Novartis Lifts Outlook With Stronger Peak Sales Forecasts(edit)
Novartis Hikes Cancer Drug Targets--Signals Billions More in Pipeline Firepower
Novartis Hikes Cancer Drug Targets--Signals Billions More in Pipeline Firepower
Novartis AG (NVS) Shareholder/Analyst Call - Slideshow
2025-11-20. The following slide deck was published by Novartis AG in conjunction with this event.
Novartis (NVS) Boosts Sales Projections and Expands Pipeline
Novartis (NVS) Boosts Sales Projections and Expands Pipeline
Novartis Expects Steady Sales Growth Through 2030
The pharma giant said it is well positioned beyond the decade, citing higher expectations for key drugs.
Novartis projects 5–6% sales growth through 2030 as peak sales outlook for Kisqali, Scemblix increases
Novartis targets 5%-6% annual sales growth until 2030 on key drugs
Switzerland's Novartis on Thursday projected currency-adjusted sales growth of 5% to 6% until 2030 for the group, underpinned by higher peak revenue expectations for its drugs Kisqali and Scemblix.
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc 1 Peak sales guidance upgraded for K...
Novartis To Build Flagship Manufacturing Hub In North Carolina
(RTTNews) - Novartis (NVS) announced plans to expand its operations in North Carolina with the creation of a new flagship manufacturing hub featuring end-to-end capabilities. This strategic investment...
Novartis (NVS) Expands US Operations with New North Carolina Hub
Novartis (NVS) Expands US Operations with New North Carolina Hub
Novartis to build manufacturing hub in North Carolina, creating 700 jobs
Novartis will expand its operations in North Carolina and build a manufacturing hub there as part of a planned $23 billion of U.S. infrastructure investment over the next five years, the Swiss pharmac...